Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.23% | -32.65% | -95.46% | -72.43% | -111.81% |
| Total Depreciation and Amortization | 434.21% | 745.83% | 1,008.33% | 613.79% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.04% | 311.50% | 257.56% | 451.32% | 1,095.19% |
| Change in Net Operating Assets | 18.49% | -122.47% | -543.39% | -124.60% | -336.16% |
| Cash from Operations | 7.42% | -27.59% | -111.70% | -53.23% | -127.58% |
| Capital Expenditure | -6,300.00% | 100.00% | -1,405.88% | -1,129.91% | 100.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -722.36% | 112.32% | 153.07% | 133.66% | 217.31% |
| Cash from Investing | -722.48% | 112.26% | 152.54% | 125.09% | 216.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 745.32% | 5,053.52% | -- | -99.86% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 745.32% | 5,053.52% | 886.67% | -99.86% | 20,924.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.72% | 91.21% | 109.70% | -109.50% | 133.03% |